Business
AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting
PRESS RELEASE AB SCIENCE TO PRESENT NEW DATA FROM MASITINIB CLINICAL PROGRAM IN AMYOTROPHIC LATERAL SCLEROSIS IN TWO PRESENTATIONS AT THE 2025 ENCALS ANNUAL MEETING MASITINIB REDUCES SERUM NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS, SUGGESTING THAT IT HAS DISEASE-MODIFYING POTENTIAL CLINICAL BENEFIT, INCLUDING CAFS AND SURVIVAL, IS GREATEST IN A SUBGROUP OF ALS PATIENTS THAT SERVES AS THE BASIS FOR THE RECENTLY AUTHORIZED PHASE 3 CONFIRMATORY STUDY Paris, May 5, 2025, 6pm CET AB Science SA (Euronext
About this update from Ab Science Sa
[{"type":"image","alt":"AB Science","displaySize":"","headline":null,"caption":"AB Science","className":"","disableSlideshowImg":false,"size":{"original":{"width":156,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AW2UM4sIueJ.X0XSJNjHhQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2","width":156,"height":160}},"lazy":false},{"type":"text","content":"PRESS RELEASE","length":13,"tagName":"p"},{"type":"text","content":"AB SCIENCE TO PRESENT NEW DATA FROM MASITINIB CLINICAL PROGRAM IN AMYOTROPHIC LATERAL SCLEROSIS IN TWO PRESENTATIONS AT THE 2025 ENCALS ANNUAL MEETING","length":150,"tagName":"p"},{"type":"text","content":"MASITINIB REDUCES SERUM NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS, SUGGESTING THAT IT HAS DISEASE-MODIFYING POTENTIAL","length":114,"tagName":"p"},{"type":"text","content":"CLINICAL BENEFIT, INCLUDING CAFS AND SURVIVAL, IS GREATEST IN A SUBGROUP OF ALS PATIENTS THAT SERVES AS THE BASIS FOR THE RECENTLY AUTHORIZED PHASE 3 CONFIRMATORY STUDY","length":168,"tagName":"p"},{"type":"text","content":"Paris, May 5, 2025, 6pm CET","length":27,"tagName":"p"},{"type":"text","content":"AB Science SA (Euronext - FR0010557264 - AB) today announced that new analyses from its phase 3 trial in amyotrophic lateral sclerosis (AB10015) and preclinical animal model data have been accepted for presentation at the ENCALS annual meeting (June 3-6, 2025, Turin, Italy). ENCALS is the European network to cure amyotrophic lateral sclerosis (ALS), with abstracts selected by the Scientific Program Committee based on scientific quality.","length":440,"tagName":"p"},{"type":"text","content":"Professor Albert Ludolph, MD, PhD, commented “These two new abstracts provide valuable data further supporting the potential for masitinib’s new phase 3 study to confirm its efficacy based on clinical endpoints and biomarkers such as NfL.”","length":239,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Professor Albert Ludolph, MD, PhD, (Chairman of the Department of Neurology at the University Hospital and Medical Faculty of Ulm), will deliver a poster presentation entitled ‘Masitinib subgroup analysis in patients prior to complete loss of function, shows increased benefit across e...